Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib
Purpose To compare the treatment response and progression-free survival (PFS) in advanced hepatocellular carcinoma (HCC) patients who received sorafenib treatment either alone or combined with radioembolization (RE). Methods Follow-up images of the patients treated within a multicenter phase II tria...
Gespeichert in:
| Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2022-11, Vol.49 (13), p.4716-4726 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4726 |
|---|---|
| container_issue | 13 |
| container_start_page | 4716 |
| container_title | European journal of nuclear medicine and molecular imaging |
| container_volume | 49 |
| creator | Öcal, Osman Schütte, Kerstin Zech, Christoph J. Loewe, Christian van Delden, Otto Vandecaveye, Vincent Verslype, Chris Gebauer, Bernhard Sengel, Christian Bargellini, Irene Iezzi, Roberto Philipp, Alexander Berg, Thomas Klümpen, Heinz J. Benckert, Julia Pech, Maciej Gasbarrini, Antonio Amthauer, Holger Bartenstein, Peter Sangro, Bruno Malfertheiner, Peter Ricke, Jens Seidensticker, Max |
| description | Purpose
To compare the treatment response and progression-free survival (PFS) in advanced hepatocellular carcinoma (HCC) patients who received sorafenib treatment either alone or combined with radioembolization (RE).
Methods
Follow-up images of the patients treated within a multicenter phase II trial (SORAMIC) were assessed by mRECIST. A total of 177 patients (73 combination arm [RE + sorafenib] and 104 sorafenib arm) were included in this post-hoc analysis. Response and progression characteristics were compared between treatment arms. Survival analyses were done to compare PFS and post-progression survival between treatment arms. Multivariate Cox regression analysis was used to compare survival with factors known to influence PFS in patients with HCC.
Results
The combination arm had significantly higher objective response rate (61.6% vs. 29.8%,
p
|
| doi_str_mv | 10.1007/s00259-022-05920-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9606085</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2728738121</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-502f41f1afdf7e17256bc3026f0572f1eb3ccaf93f7ded6db607c9a933c10c4e3</originalsourceid><addsrcrecordid>eNp9kc2OFCEUhStG44yjL-DCkLhxU3qBLig2JpOJf8kkbnThilBw6WFCQQtVk-hD-MzS02P7s3AF4XzncG9O1z2l8JICyFcVgA2qB8Z6GBSDfrzXnVJBVS9hVPePdwkn3aNarwHoyEb1sDvhg6KiOU67H-fOhSXkRLInX3oFpBgXMs5TjuG7uVVCsgVNxUqWdc6FFKy7nCoSkxyJ2ZpIXKh7gticlpJjs5Ar3JklW4xxjaYQa4oNKc-GtOeAaaktx2K4CWlLai7GYwrT4-6BN7Hik7vzrPv89s2ni_f95cd3Hy7OL3u7kZulH4D5DfXUeOclUskGMVkOTHgYJPMUJ26t8Yp76dAJNwmQVhnFuaVgN8jPuteH3N06zehsm6eYqHclzKZ809kE_beSwpXe5hutBAgYhxbw4i6g5K8r1kXPoe6XNQnzWjUTSnIhmISGPv8Hvc5rSW09zSQbJR8po41iB8qWXGtBfxyGgt7XrQ9161a3vq1bj8307M81jpZf_TaAH4DapLTF8vvv_8T-BHlBuk4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2728738121</pqid></control><display><type>article</type><title>Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib</title><source>MEDLINE</source><source>SpringerLink</source><creator>Öcal, Osman ; Schütte, Kerstin ; Zech, Christoph J. ; Loewe, Christian ; van Delden, Otto ; Vandecaveye, Vincent ; Verslype, Chris ; Gebauer, Bernhard ; Sengel, Christian ; Bargellini, Irene ; Iezzi, Roberto ; Philipp, Alexander ; Berg, Thomas ; Klümpen, Heinz J. ; Benckert, Julia ; Pech, Maciej ; Gasbarrini, Antonio ; Amthauer, Holger ; Bartenstein, Peter ; Sangro, Bruno ; Malfertheiner, Peter ; Ricke, Jens ; Seidensticker, Max</creator><creatorcontrib>Öcal, Osman ; Schütte, Kerstin ; Zech, Christoph J. ; Loewe, Christian ; van Delden, Otto ; Vandecaveye, Vincent ; Verslype, Chris ; Gebauer, Bernhard ; Sengel, Christian ; Bargellini, Irene ; Iezzi, Roberto ; Philipp, Alexander ; Berg, Thomas ; Klümpen, Heinz J. ; Benckert, Julia ; Pech, Maciej ; Gasbarrini, Antonio ; Amthauer, Holger ; Bartenstein, Peter ; Sangro, Bruno ; Malfertheiner, Peter ; Ricke, Jens ; Seidensticker, Max</creatorcontrib><description>Purpose
To compare the treatment response and progression-free survival (PFS) in advanced hepatocellular carcinoma (HCC) patients who received sorafenib treatment either alone or combined with radioembolization (RE).
Methods
Follow-up images of the patients treated within a multicenter phase II trial (SORAMIC) were assessed by mRECIST. A total of 177 patients (73 combination arm [RE + sorafenib] and 104 sorafenib arm) were included in this post-hoc analysis. Response and progression characteristics were compared between treatment arms. Survival analyses were done to compare PFS and post-progression survival between treatment arms. Multivariate Cox regression analysis was used to compare survival with factors known to influence PFS in patients with HCC.
Results
The combination arm had significantly higher objective response rate (61.6% vs. 29.8%,
p
< 0.001), complete response rate (13.7% vs. 3.8%,
p
= 0.022), and a trend for higher disease control rate (79.2% vs. 72.1%,
p
= 0.075). Progression was encountered in 116 (65.5%) patients and was more common in the sorafenib arm (75% vs. 52.0%,
p
= 0.001). PFS (median 8.9 vs. 5.4 months,
p
= 0.022) and hepatic PFS were significantly better in the combination arm (9.0 vs. 5.7 months,
p
= 0.014). Multivariate analysis confirmed the treatment arm as an independent predictor of PFS.
Conclusion
In advanced HCC patients receiving sorafenib, combination with RE has an additive anticancer effect on sorafenib treatment resulting in a higher and longer tumor response. However, the enhanced response did not translate into prolonged survival. Better patient selection and superselective treatment could improve outcomes after combination therapy.</description><identifier>ISSN: 1619-7070</identifier><identifier>ISSN: 1619-7089</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-022-05920-8</identifier><identifier>PMID: 35916920</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Anticancer properties ; Carcinoma, Hepatocellular - therapy ; Cardiology ; Disease control ; Hepatocellular carcinoma ; Humans ; Imaging ; Inhibitor drugs ; Liver cancer ; Liver Neoplasms - drug therapy ; Medicine ; Medicine & Public Health ; Multivariate analysis ; Nuclear Medicine ; Oncology ; Oncology – Digestive tract ; Original ; Original Article ; Orthopedics ; Patients ; Phenylurea Compounds - therapeutic use ; Radiology ; Regression analysis ; Response rates ; Sorafenib - adverse effects ; Sorafenib - therapeutic use ; Survival ; Targeted cancer therapy ; Tumors ; Yttrium Radioisotopes - therapeutic use</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2022-11, Vol.49 (13), p.4716-4726</ispartof><rights>The Author(s) 2022</rights><rights>2022. The Author(s).</rights><rights>The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-502f41f1afdf7e17256bc3026f0572f1eb3ccaf93f7ded6db607c9a933c10c4e3</citedby><cites>FETCH-LOGICAL-c474t-502f41f1afdf7e17256bc3026f0572f1eb3ccaf93f7ded6db607c9a933c10c4e3</cites><orcidid>0000-0002-2481-5410</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00259-022-05920-8$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00259-022-05920-8$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27903,27904,41467,42536,51298</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35916920$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Öcal, Osman</creatorcontrib><creatorcontrib>Schütte, Kerstin</creatorcontrib><creatorcontrib>Zech, Christoph J.</creatorcontrib><creatorcontrib>Loewe, Christian</creatorcontrib><creatorcontrib>van Delden, Otto</creatorcontrib><creatorcontrib>Vandecaveye, Vincent</creatorcontrib><creatorcontrib>Verslype, Chris</creatorcontrib><creatorcontrib>Gebauer, Bernhard</creatorcontrib><creatorcontrib>Sengel, Christian</creatorcontrib><creatorcontrib>Bargellini, Irene</creatorcontrib><creatorcontrib>Iezzi, Roberto</creatorcontrib><creatorcontrib>Philipp, Alexander</creatorcontrib><creatorcontrib>Berg, Thomas</creatorcontrib><creatorcontrib>Klümpen, Heinz J.</creatorcontrib><creatorcontrib>Benckert, Julia</creatorcontrib><creatorcontrib>Pech, Maciej</creatorcontrib><creatorcontrib>Gasbarrini, Antonio</creatorcontrib><creatorcontrib>Amthauer, Holger</creatorcontrib><creatorcontrib>Bartenstein, Peter</creatorcontrib><creatorcontrib>Sangro, Bruno</creatorcontrib><creatorcontrib>Malfertheiner, Peter</creatorcontrib><creatorcontrib>Ricke, Jens</creatorcontrib><creatorcontrib>Seidensticker, Max</creatorcontrib><title>Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>Purpose
To compare the treatment response and progression-free survival (PFS) in advanced hepatocellular carcinoma (HCC) patients who received sorafenib treatment either alone or combined with radioembolization (RE).
Methods
Follow-up images of the patients treated within a multicenter phase II trial (SORAMIC) were assessed by mRECIST. A total of 177 patients (73 combination arm [RE + sorafenib] and 104 sorafenib arm) were included in this post-hoc analysis. Response and progression characteristics were compared between treatment arms. Survival analyses were done to compare PFS and post-progression survival between treatment arms. Multivariate Cox regression analysis was used to compare survival with factors known to influence PFS in patients with HCC.
Results
The combination arm had significantly higher objective response rate (61.6% vs. 29.8%,
p
< 0.001), complete response rate (13.7% vs. 3.8%,
p
= 0.022), and a trend for higher disease control rate (79.2% vs. 72.1%,
p
= 0.075). Progression was encountered in 116 (65.5%) patients and was more common in the sorafenib arm (75% vs. 52.0%,
p
= 0.001). PFS (median 8.9 vs. 5.4 months,
p
= 0.022) and hepatic PFS were significantly better in the combination arm (9.0 vs. 5.7 months,
p
= 0.014). Multivariate analysis confirmed the treatment arm as an independent predictor of PFS.
Conclusion
In advanced HCC patients receiving sorafenib, combination with RE has an additive anticancer effect on sorafenib treatment resulting in a higher and longer tumor response. However, the enhanced response did not translate into prolonged survival. Better patient selection and superselective treatment could improve outcomes after combination therapy.</description><subject>Anticancer properties</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Cardiology</subject><subject>Disease control</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Imaging</subject><subject>Inhibitor drugs</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Multivariate analysis</subject><subject>Nuclear Medicine</subject><subject>Oncology</subject><subject>Oncology – Digestive tract</subject><subject>Original</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Patients</subject><subject>Phenylurea Compounds - therapeutic use</subject><subject>Radiology</subject><subject>Regression analysis</subject><subject>Response rates</subject><subject>Sorafenib - adverse effects</subject><subject>Sorafenib - therapeutic use</subject><subject>Survival</subject><subject>Targeted cancer therapy</subject><subject>Tumors</subject><subject>Yttrium Radioisotopes - therapeutic use</subject><issn>1619-7070</issn><issn>1619-7089</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kc2OFCEUhStG44yjL-DCkLhxU3qBLig2JpOJf8kkbnThilBw6WFCQQtVk-hD-MzS02P7s3AF4XzncG9O1z2l8JICyFcVgA2qB8Z6GBSDfrzXnVJBVS9hVPePdwkn3aNarwHoyEb1sDvhg6KiOU67H-fOhSXkRLInX3oFpBgXMs5TjuG7uVVCsgVNxUqWdc6FFKy7nCoSkxyJ2ZpIXKh7gticlpJjs5Ar3JklW4xxjaYQa4oNKc-GtOeAaaktx2K4CWlLai7GYwrT4-6BN7Hik7vzrPv89s2ni_f95cd3Hy7OL3u7kZulH4D5DfXUeOclUskGMVkOTHgYJPMUJ26t8Yp76dAJNwmQVhnFuaVgN8jPuteH3N06zehsm6eYqHclzKZ809kE_beSwpXe5hutBAgYhxbw4i6g5K8r1kXPoe6XNQnzWjUTSnIhmISGPv8Hvc5rSW09zSQbJR8po41iB8qWXGtBfxyGgt7XrQ9161a3vq1bj8307M81jpZf_TaAH4DapLTF8vvv_8T-BHlBuk4</recordid><startdate>20221101</startdate><enddate>20221101</enddate><creator>Öcal, Osman</creator><creator>Schütte, Kerstin</creator><creator>Zech, Christoph J.</creator><creator>Loewe, Christian</creator><creator>van Delden, Otto</creator><creator>Vandecaveye, Vincent</creator><creator>Verslype, Chris</creator><creator>Gebauer, Bernhard</creator><creator>Sengel, Christian</creator><creator>Bargellini, Irene</creator><creator>Iezzi, Roberto</creator><creator>Philipp, Alexander</creator><creator>Berg, Thomas</creator><creator>Klümpen, Heinz J.</creator><creator>Benckert, Julia</creator><creator>Pech, Maciej</creator><creator>Gasbarrini, Antonio</creator><creator>Amthauer, Holger</creator><creator>Bartenstein, Peter</creator><creator>Sangro, Bruno</creator><creator>Malfertheiner, Peter</creator><creator>Ricke, Jens</creator><creator>Seidensticker, Max</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2481-5410</orcidid></search><sort><creationdate>20221101</creationdate><title>Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib</title><author>Öcal, Osman ; Schütte, Kerstin ; Zech, Christoph J. ; Loewe, Christian ; van Delden, Otto ; Vandecaveye, Vincent ; Verslype, Chris ; Gebauer, Bernhard ; Sengel, Christian ; Bargellini, Irene ; Iezzi, Roberto ; Philipp, Alexander ; Berg, Thomas ; Klümpen, Heinz J. ; Benckert, Julia ; Pech, Maciej ; Gasbarrini, Antonio ; Amthauer, Holger ; Bartenstein, Peter ; Sangro, Bruno ; Malfertheiner, Peter ; Ricke, Jens ; Seidensticker, Max</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-502f41f1afdf7e17256bc3026f0572f1eb3ccaf93f7ded6db607c9a933c10c4e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Anticancer properties</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Cardiology</topic><topic>Disease control</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Imaging</topic><topic>Inhibitor drugs</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Multivariate analysis</topic><topic>Nuclear Medicine</topic><topic>Oncology</topic><topic>Oncology – Digestive tract</topic><topic>Original</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Patients</topic><topic>Phenylurea Compounds - therapeutic use</topic><topic>Radiology</topic><topic>Regression analysis</topic><topic>Response rates</topic><topic>Sorafenib - adverse effects</topic><topic>Sorafenib - therapeutic use</topic><topic>Survival</topic><topic>Targeted cancer therapy</topic><topic>Tumors</topic><topic>Yttrium Radioisotopes - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Öcal, Osman</creatorcontrib><creatorcontrib>Schütte, Kerstin</creatorcontrib><creatorcontrib>Zech, Christoph J.</creatorcontrib><creatorcontrib>Loewe, Christian</creatorcontrib><creatorcontrib>van Delden, Otto</creatorcontrib><creatorcontrib>Vandecaveye, Vincent</creatorcontrib><creatorcontrib>Verslype, Chris</creatorcontrib><creatorcontrib>Gebauer, Bernhard</creatorcontrib><creatorcontrib>Sengel, Christian</creatorcontrib><creatorcontrib>Bargellini, Irene</creatorcontrib><creatorcontrib>Iezzi, Roberto</creatorcontrib><creatorcontrib>Philipp, Alexander</creatorcontrib><creatorcontrib>Berg, Thomas</creatorcontrib><creatorcontrib>Klümpen, Heinz J.</creatorcontrib><creatorcontrib>Benckert, Julia</creatorcontrib><creatorcontrib>Pech, Maciej</creatorcontrib><creatorcontrib>Gasbarrini, Antonio</creatorcontrib><creatorcontrib>Amthauer, Holger</creatorcontrib><creatorcontrib>Bartenstein, Peter</creatorcontrib><creatorcontrib>Sangro, Bruno</creatorcontrib><creatorcontrib>Malfertheiner, Peter</creatorcontrib><creatorcontrib>Ricke, Jens</creatorcontrib><creatorcontrib>Seidensticker, Max</creatorcontrib><collection>SpringerOpen (Open Access)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies & Aerospace Database (1962 - current)</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Biological Science Journals</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Öcal, Osman</au><au>Schütte, Kerstin</au><au>Zech, Christoph J.</au><au>Loewe, Christian</au><au>van Delden, Otto</au><au>Vandecaveye, Vincent</au><au>Verslype, Chris</au><au>Gebauer, Bernhard</au><au>Sengel, Christian</au><au>Bargellini, Irene</au><au>Iezzi, Roberto</au><au>Philipp, Alexander</au><au>Berg, Thomas</au><au>Klümpen, Heinz J.</au><au>Benckert, Julia</au><au>Pech, Maciej</au><au>Gasbarrini, Antonio</au><au>Amthauer, Holger</au><au>Bartenstein, Peter</au><au>Sangro, Bruno</au><au>Malfertheiner, Peter</au><au>Ricke, Jens</au><au>Seidensticker, Max</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><date>2022-11-01</date><risdate>2022</risdate><volume>49</volume><issue>13</issue><spage>4716</spage><epage>4726</epage><pages>4716-4726</pages><issn>1619-7070</issn><issn>1619-7089</issn><eissn>1619-7089</eissn><abstract>Purpose
To compare the treatment response and progression-free survival (PFS) in advanced hepatocellular carcinoma (HCC) patients who received sorafenib treatment either alone or combined with radioembolization (RE).
Methods
Follow-up images of the patients treated within a multicenter phase II trial (SORAMIC) were assessed by mRECIST. A total of 177 patients (73 combination arm [RE + sorafenib] and 104 sorafenib arm) were included in this post-hoc analysis. Response and progression characteristics were compared between treatment arms. Survival analyses were done to compare PFS and post-progression survival between treatment arms. Multivariate Cox regression analysis was used to compare survival with factors known to influence PFS in patients with HCC.
Results
The combination arm had significantly higher objective response rate (61.6% vs. 29.8%,
p
< 0.001), complete response rate (13.7% vs. 3.8%,
p
= 0.022), and a trend for higher disease control rate (79.2% vs. 72.1%,
p
= 0.075). Progression was encountered in 116 (65.5%) patients and was more common in the sorafenib arm (75% vs. 52.0%,
p
= 0.001). PFS (median 8.9 vs. 5.4 months,
p
= 0.022) and hepatic PFS were significantly better in the combination arm (9.0 vs. 5.7 months,
p
= 0.014). Multivariate analysis confirmed the treatment arm as an independent predictor of PFS.
Conclusion
In advanced HCC patients receiving sorafenib, combination with RE has an additive anticancer effect on sorafenib treatment resulting in a higher and longer tumor response. However, the enhanced response did not translate into prolonged survival. Better patient selection and superselective treatment could improve outcomes after combination therapy.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>35916920</pmid><doi>10.1007/s00259-022-05920-8</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-2481-5410</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1619-7070 |
| ispartof | European journal of nuclear medicine and molecular imaging, 2022-11, Vol.49 (13), p.4716-4726 |
| issn | 1619-7070 1619-7089 1619-7089 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9606085 |
| source | MEDLINE; SpringerLink |
| subjects | Anticancer properties Carcinoma, Hepatocellular - therapy Cardiology Disease control Hepatocellular carcinoma Humans Imaging Inhibitor drugs Liver cancer Liver Neoplasms - drug therapy Medicine Medicine & Public Health Multivariate analysis Nuclear Medicine Oncology Oncology – Digestive tract Original Original Article Orthopedics Patients Phenylurea Compounds - therapeutic use Radiology Regression analysis Response rates Sorafenib - adverse effects Sorafenib - therapeutic use Survival Targeted cancer therapy Tumors Yttrium Radioisotopes - therapeutic use |
| title | Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T15%3A03%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Addition%20of%20Y-90%20radioembolization%20increases%20tumor%20response%20and%20local%20disease%20control%20in%20hepatocellular%20carcinoma%20patients%20receiving%20sorafenib&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=%C3%96cal,%20Osman&rft.date=2022-11-01&rft.volume=49&rft.issue=13&rft.spage=4716&rft.epage=4726&rft.pages=4716-4726&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-022-05920-8&rft_dat=%3Cproquest_pubme%3E2728738121%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2728738121&rft_id=info:pmid/35916920&rfr_iscdi=true |